Mortality Risk of Patients With COVID-19 Prescribed SSRIs

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, NOVEMBER 15, 2021

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2021.33090?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=111521

About JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

What The Study Did: Researchers analyzed electronic health records for about 83,000 patients diagnosed with COVID-19, including 3,401 patients prescribed selective serotonin reuptake inhibitors (SSRIs), to investigate whether SSRIs are associated with a lower risk of death among patients with COVID-19.

Authors: Marina Sirota, Ph.D., of the University of California, San Francisco, and David K. Stevenson, M.D., of the Stanford University School of Medicine in Stanford, California, are the corresponding authors.

 

(doi:10.1001/jamanetworkopen.2021.33090)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.